The verdict of the US district court in New Jersey is that Shilpa's generic infringes a US patent on multikinase inhibitor ...

As a result of the decision, Shilpa will not be eligible to receive FDA approval for its lenvatinib mesylate generic until February 2036.

Japanese drugmaker Eisai (TYO: 4523) said yesterday that it has received a favorable decision regarding the lawsuit filed in ...

The oncology and neurology pharmaceutical company from Japan announced rolling layoffs back in February impacting 57 ...

today announced that the analysis of a combination study of E7386(*1), created through collaboration research with Eisai Co., ...

Eisai shares fell sharply after its Alzheimer’s drug failed to secure marketing approval in the European Union. Shares were recently 12% lower at 5,852 yen, or about $38.06, Monday morning after ...

Patients with early Alzheimer’s disease treated with a medication developed by Eisai and Biogen for up to three years experienced less cognitive decline than what’s expected of untreated ...

A readily available sleep aid has been shown to have a surprising side effect on brain health, seemingly protecting the organ ...

NUTLEY, N.J., May 20, 2025 /PRNewswire/ -- Eisai announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2025 American Society of Clinical ...

Eisai and Biogen have received marketing authorisation (MA) from the European Commission (EC) for Leqembi (lecanemab) to treat Alzheimer's disease. This authorisation makes the amyloid-beta (Aβ ...

Eisai Co., Ltd. and Biogen Inc. announced that the European Commission has granted marketing authorization for lecanemab, marketed as Leqembi®, making it the first therapy in the EU to target an ...